174 related articles for article (PubMed ID: 36418671)
1. Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Gunawardana M; Remedios-Chan M; Sanchez D; Fanter R; Webster S; Webster P; Moss JA; Trinh M; Beliveau M; Ramirez CM; Marzinke MA; Kuo J; Gallay PA; Baum MM
Pharm Res; 2023 Jul; 40(7):1657-1672. PubMed ID: 36418671
[TBL] [Abstract][Full Text] [Related]
2. Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis.
Gunawardana M; Remedios-Chan M; Sanchez D; Webster S; Castonguay AE; Webster P; Buser C; Moss JA; Trinh M; Beliveau M; Hendrix CW; Marzinke MA; Tuck M; Caprioli RM; Reyzer ML; Kuo J; Gallay PA; Baum MM
Sci Rep; 2022 May; 12(1):8224. PubMed ID: 35581262
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
Gunawardana M; Remedios-Chan M; Miller CS; Fanter R; Yang F; Marzinke MA; Hendrix CW; Beliveau M; Moss JA; Smith TJ; Baum MM
Antimicrob Agents Chemother; 2015 Jul; 59(7):3913-9. PubMed ID: 25896688
[TBL] [Abstract][Full Text] [Related]
4. Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques.
Gatto GJ; Krovi A; Li L; Massud I; Holder A; Gary J; Mills P; Mitchell J; Luecke E; Demkovich ZR; Heneine W; García-Lerma JG; Marzinke MA; Brand RM; Dobard CW; Johnson LM; Van Der Straten A
Front Pharmacol; 2022; 13():923954. PubMed ID: 35928266
[TBL] [Abstract][Full Text] [Related]
5. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
[TBL] [Abstract][Full Text] [Related]
6. Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates.
Pons-Faudoa FP; Di Trani N; Capuani S; Hernandez N; Wood AM; Nehete B; Niles J; Shelton KA; Kezar S; Bushman LR; Chua CYX; Ittmann MM; Anderson PL; Nehete PN; Arduino RC; Nichols JE; Grattoni A
J Control Release; 2023 Jun; 358():116-127. PubMed ID: 37120032
[TBL] [Abstract][Full Text] [Related]
7. A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
Zane D; Roller S; Shelton J; Singh R; Jain R; Wang Y; Yang B; Felx M; Alessi T; Feldman PL
Microbiol Spectr; 2021 Sep; 9(1):e0033921. PubMed ID: 34190595
[TBL] [Abstract][Full Text] [Related]
8. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
Mandal S; Prathipati PK; Sunagawa SW; Destache CJ
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526487
[TBL] [Abstract][Full Text] [Related]
9. CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women.
Gengiah TN; Abdool Karim Q; Harkoo I; Mansoor L; Zuma NY; Radebe P; Samsunder N; Baxter C; Maharaj B; Baum MM; Moss JA; Pozzetto B; Hankins C; Abdool Karim S
BMJ Open; 2022 Jan; 12(1):e052880. PubMed ID: 34992111
[TBL] [Abstract][Full Text] [Related]
10. Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis.
Gunawardana M; Remedios-Chan M; Sanchez D; Webster S; Galvan P; Fanter R; Castonguay AE; Webster P; Moss JA; Kuo J; Gallay PA; Vincent KL; Motamedi M; Weinberger D; Marzinke MA; Hendrix CW; Baum MM
Front Pharmacol; 2020; 11():569373. PubMed ID: 33536904
[TBL] [Abstract][Full Text] [Related]
11. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.
Sizovs A; Pons-Faudoa FP; Malgir G; Shelton KA; Bushman LR; Chua CYX; Anderson PL; Nehete PN; Sastry KJ; Grattoni A
Int J Pharm; 2020 Sep; 587():119623. PubMed ID: 32663582
[TBL] [Abstract][Full Text] [Related]
12. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
13. Effects of Polymer Blending on the Performance of a Subcutaneous Biodegradable Implant for HIV Pre-Exposure Prophylaxis (PrEP).
Li L; Areson C; van der Straten A; Johnson LM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207212
[TBL] [Abstract][Full Text] [Related]
14. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
[TBL] [Abstract][Full Text] [Related]
15. Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
Parsons TL; Gwenden KN; Marzinke MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32540983
[TBL] [Abstract][Full Text] [Related]
16. Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP).
Li L; Johnson LM; Krovi SA; Demkovich ZR; van der Straten A
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33167509
[TBL] [Abstract][Full Text] [Related]
17. A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.
Schlesinger E; Johengen D; Luecke E; Rothrock G; McGowan I; van der Straten A; Desai T
Pharm Res; 2016 Jul; 33(7):1649-56. PubMed ID: 26975357
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Massud I; Cong ME; Ruone S; Holder A; Dinh C; Nishiura K; Khalil G; Pan Y; Lipscomb J; Johnson R; Deyounks F; Rooney JF; Babusis D; Park Y; McCallister S; Callebaut C; Heneine W; García-Lerma JG
J Infect Dis; 2019 Oct; 220(11):1826-1833. PubMed ID: 31362305
[TBL] [Abstract][Full Text] [Related]
19. Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate.
Simpson SM; Widanapathirana L; Su JT; Sung S; Watrous D; Qiu J; Pearson E; Evanoff A; Karunakaran D; Chacon JE; Kiser PF
Pharm Res; 2020 Apr; 37(4):83. PubMed ID: 32296951
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
Romano JW; Baum MM; Demkovich ZR; Diana F; Dobard C; Feldman PL; Garcia-Lerma JG; Grattoni A; Gunawardana M; Ho DK; Hope TJ; Massud I; Milad M; Moss JA; Pons-Faudoa FP; Roller S; van der Straten A; Srinivasan S; Veazey RS; Zane D
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):409-420. PubMed ID: 33913760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
